文献速递消化道肿瘤与早癌消化内镜

两样本FIT结果不一致者中四分之一晚期肿瘤检出

A Quarter of Participants With Advanced Neoplasia Have Discordant Results From 2-Sample Fecal Immunochemical Tests for Colorectal Cancer Screening.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-09-26

在荷兰国家结直肠癌筛查项目内开展前瞻性比较准确性研究,42179名55–75岁初次筛查者于同一份粪便上完成两种定量FIT(FOB-Gold与OC-Sensor,阳性阈值≥15 μg血红蛋白/克粪便),任一阳性者行结肠镜。共21078人纳入,883人(4.2%)两法结果不一致,其中187人(21%)检出晚期肿瘤;687例晚期肿瘤中187例(27%)仅一种FIT阳性。

要点

  • 两样本FIT结果不一致者中21%检出晚期肿瘤,应行结肠镜。
  • 结肠镜确诊的晚期肿瘤中27%仅一种FIT阳性。
  • 双阳性者晚期肿瘤检出率为43%,显著高于不一致者的21%(p < .001)。

核心结论

  • 在两样本FIT筛查中,结肠镜检出晚期肿瘤者超过四分之一存在两法结果不一致。
  • 两法结果不一致者中约五分之一检出晚期肿瘤,此类人群应接受结肠镜检查。

研究设计与样本

  • 荷兰国家结直肠癌筛查项目内的大型前瞻性比较准确性研究(试验注册号NTR5874)。
  • 2016年5月至2017年3月招募42179名55–75岁初次筛查者,在同一份粪便上完成两种定量FIT。
  • 任一FIT阳性(≥15 μg血红蛋白/克粪便)者邀请行结肠镜,以结肠镜检出晚期肿瘤为参考标准。
  • 共21078人纳入分析(参与率50%)。

主要发现

  • 19032人(90%)两法均阴性,1163人(5.5%)两法均阳性,883人(4.2%)结果不一致。
  • 双阳性者中500人(43%)检出晚期肿瘤,不一致者中187人(21%)检出晚期肿瘤(p < .001)。
  • 687例结肠镜确诊的晚期肿瘤中,187例(27%)仅一种FIT阳性。

关键数值与推荐

  • FIT阳性阈值定义为≥15 μg血红蛋白/克粪便。
  • 两样本FIT结果不一致者应行结肠镜检查。

临床怎么用

  • 对两样本FIT结果不一致的筛查对象,应按阳性处理并安排结肠镜。
  • 解读两样本FIT结果时需注意不一致结果仍伴有一定晚期肿瘤检出风险。

局限性

  • 原文摘要未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Some colorectal cancer (CRC) screening programs use 2-sample fecal immunochemical tests (FITs). We aimed to assess advanced neoplasia (AN) yield of 2 different FIT assays performed on the same bowel movement and have discordant results. METHODS: We conducted a large prospective comparative accuracy study within the Dutch national CRC screening program to evaluate 2 quantitative FIT assays (FOB-Gold, Sentinel, Italy and OC-Sensor, Eiken, Japan) with comparable performance characteristics. We asked 42,179 screening-naïve individuals, 55-75 years old, to perform both tests on the same bowel movement, from May 2016 through March 2017. Participants with ≥1 positive test result (≥15 μg hemoglobin/gram feces) were invited for colonoscopy examination. Detection of AN by colonoscopy was the reference standard. RESULTS: A total of 21,078 participants (50% participation rate) were included. FIT results were both negative for 19,032 participants (90%), both positive for 1163 participants (5.5%), and discordant for 883 participants (4.2%). AN was detected in 500 participants with 2 positive FIT results (43%) compared to 187 with discordant FIT results (21%) (p < .001). Of the 687 participants found to have AN by colonoscopy, 187 had only 1 positive FIT result (27%). CONCLUSION: In a large 2-sample FIT-based CRC screening study, more than a quarter of participants in whom AN was detected by colonoscopy in the first screening round had discordant FIT results. AN was detected in one-fifth of those with FIT discordance. Participants with discordant results from 2 FITs should undergo colonoscopy. (www.trialregister.nl; no. NTR5874).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wieten E, de Klerk CM, Lansdorp-Vogelaar I, et al. A Quarter of Participants With Advanced Neoplasia Have Discordant Results From 2-Sample Fecal Immunochemical Tests for Colorectal Cancer Screening. Clin Gastroenterol Hepatol. 2019. PMID: 31563557. doi:10.1016/j.cgh.2019.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。